Hatena, Minkabu the Infonoid, etc.

＜175A＞Will SMART Co., Ltd. Zenrin Co., Ltd. Stock Ownership Ratio -% → 44.67% Reporting Obligation Date 2024/04/16 ＜2586＞Frutta Fruta Evo Fund Co., Ltd. Stock Ownership Ratio 40.49% → 40.02% Reporting Obligation Occurrence Date 2024/04/12 ＜3930＞Hatena Co., Ltd. SBI Securities Stock Ownership Ratio 5.09% → 1.80% Report

Fisco JapanApr 21 20:17 ET

Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 4/9)

<1439>[Good Material] ――――――――――■Yasue Corporation [Tokyo Stock Exchange S] March order volume increased 10.7% from the same month last year, surpassing the previous year's results for the first time in 2 months. ■Tabio <2668>[Tokyo Stock Exchange S]'s current financial results for the current fiscal year will increase 11%. ■Can Do <2698>[Tokyo Stock Exchange S] Current fiscal year earnings will increase 69%. ■Pal Group Holdings <2726>[Tokyo Stock Exchange P]'s current financial results increased 8% to the highest profit for the 3rd consecutive term. <2923>■Sato Foods [Tokyo Stock Exchange

MinkabuApr 9 07:49 ET

Is push buying dominant due to steady growth and expectations of a drop in US interest rates

[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop steadily. In the US stock market yesterday 3rd, the Dow Average continued to fall slightly for 3 days to 39127.14 dollars, which depreciated by 43.10 dollars (-0.11%). ADP employment statistics exceeded expectations, and the view that interest rate cuts were even farther away weighed on stock prices. Meanwhile, in addition to the unexpected decline in the March ISM non-manufacturing business climate index, Chairman Powell of the Federal Reserve (Fed) continues to suggest the possibility of interest rate cuts by the end of the year

Fisco JapanApr 3 19:20 ET

LaQuoria Drug Discovery, Reprocel, etc.

＜3195＞Genepa launches a new business (Unique Stores Platform business) ＜4579＞LaQuolia Pharmaceutical signed an agreement with Velovia Pharma, LLC (US) on the development of pet pharmaceuticals ＜4978＞Reprocel research and development business “Research and development to begin corporate clinical trials of cell therapy using cell transplantation of human iPS cell-derived glial progenitor cells (iRP) for amyotrophic lateral sclerosis (ALS)” ANED Public Recruitment Project “Regenerative Medicine

Fisco JapanApr 3 18:30 ET

Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 4/3)

Meiho Facility Works has been selected as a “DX certified operator” by the Ministry of Economy, Trade and Industry.

MinkabuApr 3 07:00 ET

ReproCELL Sees FY Net Y148.00M

ReproCELL Inc. also released the following forecasts: GROUP Year Ending Mar 2024 Revenue Y3.05 bln Operating Profit (Y110.00 mln) Pretax Pro

Dow JonesFeb 9 01:02 ET